Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of crisaborole (Staquis) for treatment of atopic dermatitis

Crisaborole is a phosphodiesterase‑4 inhibitor that suppresses secretion of certain cytokines and improves skin barrier function through its anti -inflammatory effects. It will be available as 20 mg/g ointment.


European Medicines Agency